Articles from Vizgen, Inc.

Vizgen, Inc., a spatial multi-omics innovator accelerating biological discovery and new drug development, today announced that it will present new spatial multi-omics data at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting on November 7-10, 2025 in National Harbor, Maryland. The company will showcase how researchers can generate a combination of high-quality RNA and protein data via Vizgen’s bioinformatics technology.

Vizgen, Inc., a life sciences company advancing spatial multi-omics, today announced the publication of a study in Nature Neuroscience that showcases the use of the MERSCOPE® platform for better understanding the processes that occur during aging. This landmark study, entitled “Microglia activation orchestrates CXCL10-mediated CD8+ T cell recruitment to promote aging-related white matter degeneration,” was published online in late May and is featured as the cover story of the June issue of Nature Neuroscience.

Vizgen, Inc., the life sciences company revolutionizing spatial genomics and proteomics research and driving innovation in spatial multi-omics, today announced the broad global commercial availability of MERFISH 2.0™, a next-generation spatial transcriptomics chemistry designed to drive breakthroughs in foundational biological research. The company also announced the expansion of fully configurable OmniVUE™ spatial proteomics panels with validated biomarkers as research and development tools to accelerate the development of Antibody-Drug Conjugates (ADC) therapies. Vizgen will present new data showing how MERFISH 2.0 and the ADC OmniVUE panels are complementary in a multi-omics analysis study at the American Association for Cancer Research (AACR) Annual Meeting, April 25-30, 2025.

Vizgen, Inc., the life sciences company revolutionizing spatial genomics research and driving innovation in spatial multi-omics, today released an open letter in response to the settlement of litigation between Vizgen, Harvard University and 10X Genomics in the United States District Court for the District of Delaware.

Vizgen, Inc., the life sciences company revolutionizing spatial genomics research and driving innovation in spatial multi-omics, today announced two key appointments aimed at advancing the company’s future strategy and execution. Christian Uhrich, investment director at M Ventures − the strategic corporate venture capital arm of Merck KGaA, Darmstadt, Germany − has joined Vizgen’s Board of Directors to support the company’s long-term growth strategy following a recent investment. Further, Chad Brown has been named Vizgen’s Chief Commercial Officer (CCO). He brings over 30 years of experience in sales, marketing, and leadership at companies such as NanoString, QIAGEN, and Roche Diagnostics, demonstrating a track record of commercial excellence.

Vizgen, Inc., the life sciences company revolutionizing spatial genomics research and driving innovation in spatial multi-omics, today announced the official launch of its Certified Service Provider (CSP) program. The CSP initiative aims to empower researchers around the world by expanding access to Vizgen’s MERSCOPE® and MERSCOPE Ultra™ Platforms for high-quality spatial genomics services through a network of certified academic and commercial services organizations, with the training, expertise and technology infrastructure required to provide full-service Vizgen solutions for breakthrough discoveries.

Vizgen, Inc., a life science company dedicated to improving human health by visualizing single-cell spatial genomics information, and Ultivue, Inc., a market leader in multiplex proteomic biomarker detection and advanced AI-driven spatial tissue profiling, today announced a merger. The companies are combining to establish a single organization uniquely positioned to drive future technology breakthroughs and respond to researchers’ desire for unified solutions in spatial multi-omics.

Vizgen, Inc., the life science company dedicated to improving human health through single-cell spatial genomics, proudly announces the first global shipments of the highly anticipated MERSCOPE Ultra™ Platform. This milestone marks a significant step for Vizgen as it begins delivering this next-generation technology to leading research institutions around the world. Among the first to receive the platform are the Institut Pasteur in Paris, France, The Translational Genomics Research Institute (TGen), part of City of Hope in Phoenix, Arizona, and other leading research institutes.

Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, announced today the issuance by the US Patent Office of a patent that covers the in situ imaging of the spatial transcriptome. U.S. Patent No. 11,959,075 is for robust multiplex imaging of RNA and its spatial organization in a sample.

Vizgen, Inc. the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today unveiled the MERSCOPE® Ultra Platform and MERFISH 2.0 chemistry at the AACR 2024 Annual Meeting. These powerful tools are uniquely suited to supporting basic and translational research and will be commercially available in the second half of the year.

Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, is very pleased to announce that, on March 7, 2024, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) denied 10x Genomics Inc.’s petition to institute an Inter Partes Review proceeding (IPR) against U.S. Patent 11,098,303 B2 (‘303 Patent), which Vizgen licenses exclusively from Harvard University. This is the latest in a series of rulings against 10x in its aggressive attempts to weaponize patents to dominate the field through baseless litigation.

Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has announced a significant capital raise to fuel its continued growth and execution of long-term vision. At the same time, the company has also taken steps to streamline its operations and reduce headcount. These measures come in response to unlawful monopolistic conduct by 10x Genomics and Harvard University, Vizgen’s own licensor—including baseless patent litigation in the U.S. and Europe.

Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has unveiled enhanced MERFISH chemistry along with its 2024 product roadmap. In addition to the announcement of these product developments, Vizgen will be presenting three posters at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting, in Orlando, Florida, this week.

Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has announced a partnership with Scale Biosciences (ScaleBio) to combine their single-cell and spatial technologies for enhanced data analysis at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting in Orlando, Florida.

Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced that five of the ten studies published in the December 13 issue of Nature, which unveiled the first full cellular map of the adult mouse brain, leveraged MERFISH technology for spatial genomics insights. Researchers identified more than 5,300 cell types across 32 million cells, more than ever known before, and were able to map their location within the brain.

Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today noted the order on Vizgen’s counterclaims against Plaintiffs 10x Genomics, Inc. (“10x”) and Harvard College (“Harvard”) issued by the United States District Court for the District of Delaware on July 10, 2023.

Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe.